SV

Sunil Vaidya Dyaneshwar

Active Director Director DIN 02843110
DIN 02843110 First appointment Jul 2010 Primary industry Healthcare
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2010
Shareholding value β€’β€’β€’β€’ Premium profile

About Sunil Vaidya Dyaneshwar

Data last updated:

Sunil Vaidya Dyaneshwar is a Director at Gelwell Pharmadvice Private Limited (since 2010). The company operates in Healthcare.

DIN 02843110
Primary Designation Director
Industry Healthcare
First Appointment 20 Jul 2010
Oldest Company Age 16 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Gelwell Pharmadvice Private Limited U93090MH2010PTC205708
Director20 Jul 20102010Active

Board colleagues of Sunil Vaidya Dyaneshwar

NameDINCompanyDesignation
Ramesh Joshi Balkrishna02843164Gelwell Pharmadvice Private LimitedDirector

Directorship timeline

Open interactive timeline →
Gelwell Pharmadvice Private Limited
Premium access

Shareholding and investment profile for Sunil Vaidya Dyaneshwar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sunil Vaidya Dyaneshwar

Sunil Vaidya Dyaneshwar currently holds 1 directorship: Gelwell Pharmadvice Private Limited (Director, since 20 Jul 2010).

Sunil Vaidya Dyaneshwar was first appointed on 20 Jul 2010 as Director at Gelwell Pharmadvice Private Limited.

The current boards of Sunil Vaidya Dyaneshwar's companies include Ramesh Joshi Balkrishna (Gelwell Pharmadvice Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available